Trials / Approved For Marketing
Approved For MarketingNCT03400098
ATTR Expanded Access Program (EAP) by Ionis
Expanded Access Program for Inotersen (ISIS 420915) in Patients With Hereditary Transthyretin Amyloidosis (hATTR)
- Status
- Approved For Marketing
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
The purpose of this program is to provide expanded access to Inotersen for up to 100 Patients with Hereditary Transthyretin Amyloidosis (hTTR).
Detailed description
The Program is intended to provided expanded access to Inotersen for eligible patients with hATTR who have limited or no available treatment options.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inotersen | Inotersen administered by subcutaneous (SC) injections in the abdomen, thigh, or upper arm |
Timeline
- First posted
- 2018-01-17
- Last updated
- 2019-08-05
Source: ClinicalTrials.gov record NCT03400098. Inclusion in this directory is not an endorsement.